The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | OPTIMISMM study update
Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, discusses data coming from the OPTIMISMM study (NCT01734928). This sub-analysis looked at patients with multiple myeloma treated with pomalidomide, bortezomib and dexamethasone after one prior line of therapy in patients pre-treated with bortezomib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
